Clinical trials: Immunosuppression After Liver Transplantation
Liver Carcinoma
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.
- Trial name
- NCT00328770
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Alberta
Single Transplant, 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS
De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal
Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").
- Trial name
- NCT05808192
- Testing
- Immunosuppressive
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- University of Rome Tor Vergata
Asses Immunosuppression Modulation on Renal Recovery Post LT
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard…
- Trial name
- NCT04104438
- Testing
- Basiliximab 20 MG
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Fady M Kaldas, M.D., F.A.C.S.
Liver Disease
Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation
The purpose of the study is to assess the safety and efficacy of mycophenolate mofetil alone, or with reduced dose cyclosporine (CsA) or tacrolimus, for immunosuppression long-term after liver transplantation, in an attempt to…
- Trial name
- NCT00206076
- Testing
- mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Albert Einstein Healthcare Network
Recipients of Liver Transplant
Envarsus XL Immunosuppression Following Liver Transplantation
The standard immunosuppressive regimen for liver transplantation includes twice daily tacrolimus (Prograf). In other transplantation models, there are potential benefits to extended release formulations as lower peak…
- Trial name
- NCT03828058
- Testing
- Envarsus XR, Prograf
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Methodist Healthcare - Memphis
Liver Graft Dysfunction
Delayed CNI-based Immunosuppression With Advagraf After MELD-based Liver Transplantation
Prolonged-release low-dose Advagraf should better protect from CNI-side effects compared to standard immunosuppressive regiments while the rate of rejection is not increased and thus graft function is well maintained.
- Trial name
- IMUTECT (NCT01781195)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Liver Transplantation
Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation
Most patients who get a liver transplant must take immunosuppressants for the rest of their lives. However, this has occurred at the expense of chronic CNI toxicity, e.g.
- Trial name
- NCT02736227
- Testing
- Tacrolimus Withdrawal and Everolimus Monotherapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Immunosuppression
Fibroscan to Guide Post Transplant Immunosuppression Minimization
Following Liver transplantation, recipients remain on life long immunosuppression. Prolonged exposure to immunosuppression is associated with side effects and complications including kidney dysfunction, diabetes, heart disease…
- Trial name
- NCT07206277
- Testing
- Immunosuppression reduction
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Alberta
Immunosuppression, Hepatocellular Carcinoma
Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids
The purpose of this study was to evaluate the safety and efficacy of a steroid-free immunosuppression protocol in Hepatocellular Carcinoma (HCC) patients.
- Conditions
- Immunosuppression, Hepatocellular Carcinoma, Liver Transplantation, Post-operative Complications
- Trial name
- NCT01137084
- Testing
- solu medrol, a steroid-free immunosuppression protocol
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Kidney Transplant Recipients, Liver Transplant Recipients
COVID Protection After Transplant-Immunosuppression Reduction
This study will enroll individuals who have: Completed primary series of mRNA COVID-19 vaccine, and An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
- Trial name
- CPAT-ISR (NCT05077254)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen
- Where
- 15 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplantation, Chronic Renal Insufficiency
Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation
A prospective, non-randomized two stage monocentric phase II clinical trial to evaluate a de-novo calcineurin-inhibitor (CNI)-free immunosuppressive regimen based on induction therapy with anti-CD25 monoclonal anti-body…
- Trial name
- CILT (NCT00890253)
- Testing
- Basiliximab (Simulect), Myfortic, everolimus
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- Armin Goralczyk
Hepatitis C, Liver Cirrhosis
Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid
The aim of this study is to compare immunosuppression protocol of tacrolimus + MMF with that of tacrolimus + steroid for preventing recurrence of hepatitis C after living donor liver transplantation.
- Trial name
- NCT00469131
- Testing
- tacrolimus + steroid, tacrolimus + mycophenolate mofetil
- Where
- Japan
- Volunteers
- 79 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Liver Allograft, Liver Diseases
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)
The overall aim of this study is nephroprotection based on a calcineurin inhibitor (CNI)-free therapy beyond year one after orthotopic liver transplantation (OLT) in highly pre-selected patients with low rejection risk.
- Conditions
- Liver Allograft, Liver Diseases, Liver Transplantation
- Trial name
- ALTERNATION (NCT07739914)
- Testing
- Everolimus, Tacrolimus or Cyclosporine
- Where
- 16 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Hannover Medical School
Liver Transplantation, Immunosuppression
Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)
World Health Organization considers non-adherence has a strong negative impact on the health of patients with chronic diseases. In transplantation, adherence to immunosuppressive drug regimens associates with late rejection and…
- Trial name
- EASY (NCT06354179)
- Testing
- XR-tacrolimus QD + MMF BID then MMF QD, XR-tacrolimus QD + MMF BID, LCP-tacrolimus QD + MMF QD then MMF QD
- Where
- 18 sites in France
- Volunteers
- 162 people
- Sponsor
- University Hospital, Limoges
SARS-CoV-2 Vaccination, Liver Transplantation
Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients
To investigate the variations in the humoral response to vaccines for the prevention of COVID-19 in liver transplant patients based on the type of immunosuppressive therapy adopted (tacrolimus based vs no-tacrolimus based) and…
- Trial name
- NCT05490342
- Testing
- Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- University of Rome Tor Vergata
Hepatic Insufficiency
Extracorporeal Photopheresis After Liver Transplant
The purpose of this study is to determine the safety of photopheresis for prophylaxis of allograft rejection in patients who are being withdrawal immunosuppression after liver transplantation.
- Trial name
- NCT02090621
- Testing
- Extracorporeal photopheresis
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Transplant Complication
Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation
To develop a prospective quantitative liver allograft monitoring protocol and retrospectively validate the use of Phenotypic personalized medicine (PPM) in immunosuppression dosing in liver transplant recipients.
- Trial name
- TGI (NCT06063213)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Florida
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Heart Transplantation, Liver Transplantation
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a single intravenous infusion.
- Conditions
- Heart Transplantation, Liver Transplantation, Bone Resorption
- Trial name
- CTX (NCT00297830)
- Testing
- Zoledronic acid, Alendronate
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Columbia University
Liver Transplant Rejection, Immunosuppression
Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial
Adult patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after orthotropic liver transplantation (OLTx) on prolonged released Tacrolimus variant in 1:1 ratio …
- Trial name
- NCT03603548
- Testing
- Envarsus, Advagraf
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Medical University of Warsaw